Mandate

VINGE ADVISES HEXATRONIC IN CONJUNCTION WITH ACQUISITION OF TD FIBEROPTIK

March 02, 2015

Vinge has advised Hexatronic Group AB (publ) listed on NASDAQ Stockholm First North in conjunction with the acquisition of all shares in Tele & Data Fiberteknik I Örebro AB. TD Fiberoptik manufactures and sells products and solutions for passive fiber networks primarily for the telecommunications market.  TD Fiberoptik has approximately 50 employees in Sweden and Norway and an annual turnover of approximately SEK 125 million with an EBITDA margin of approximately 12 per cent.

The purchase price on a debt free basis amounts to approximately SEK 80 million, approximately SEK 70 million of which is paid in cash and approximately SEK 10 million through in issue in kind to the seller.

Vinge’s team consisted of responsible partner Anders Strid together with, among others, associates Amanda Winberg (project manager), Frida Bäckergren, Frida Mattsson (employment), Karin Wissenius (competition) and corporate assistant, Josefine Halldén.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025